The clinical treatment of all forms of cancer rests increasingly on the combination of surgery, radiotherapy, and chemotherapy. Each of these disciplines has its limitations. Radiotherapy can only be applied to a limited field in adequate dosage for cure, except in the treatment of tumours extremely sensitive to X-radiation. Chemotherapy is so far limited by the generally toxic effect on all the cells of the body, as well as on those of the tumour. It would not be unreasonable to hope that a combination of these three would, therefore, offer the best prospects for the patient while awaiting the better understanding of the basic factors controlling the growth of cancer cells.
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Of the chemotherapeutic agents available, only three appear at present to survival. The critical time of appearance of secondary tumours after the recognition of the primary is within the first year, and 950% of secondaries will appear within 12-18 months following operation. The best results were in those children who were treated before the age of 1 year, who gave an 85 % survival rate.
The introduction of actinomycin D has improved the over-all rate of survival, according to Collins' rule, to 67%, and in Because few patients presented initially with lung metastases (7 out of the last 75 cases) but developed them usually within three months of operation with radiotherapy (19 out of the remaining 68 cases), he suggested that with the combination ofactinomycin D, prophylactic irradiation of the lung fields might be considered. He questioned the value of treating the local area of nephrectomy with X-radiation, unless this were considered, after confirmation of the diagnosis by biopsy, as a pre-operative measure along with actinomycin D. He has carried out this treatment twice with surival up to 14 months.
G. W. Dorman also questioned the value of irradiating the renal bed following removal of an encapsulated tumour, as there can be crippling complications of radiotherapy in young babies. He had a group of 24 patients in whom conventional therapy with surgery, radiotherapy, and actinomycin D had failed. They were treated with cyclophosphamide with a satisfactory response in 10, with freedom from symptoms and pulmonary metastases for about 12 months. Pulmonary metastases, however, appeared after that time. There was prolongation of life in all 24 patients.
In a group of 13 patients who appeared to be resistant to actinomycin D, he used vincristine sulphate which showed encouraging results in 9. To be effective, a rapid response was necessary, and if there was no response within three weeks of initiating vincristine then the tumours were usually resistant to this drug. He favoured the combination of actinomycin D and vincristine as initial treatment along with surgery in the patients presenting with pulmonary metastases.
Including those on the Panel, speakers from various centres took part in the discussion, including A. Murray Clarke (Melbourne), D. G. Young (London), J. MacLelland (Edinburgh), A. Jolleys (Manchester). The following conclusions were drawn.
(1) Diagnosis. Even with biopsy, errors in diagnosis could occur in a few instances, which could prove disastrous to the patient. Every diagnostic aid including selective aortogram should, therefore, be employed, especially in the patient whose clinical picture was unusual. Histologically the cystic tumour, and those showing tubular structures, seemed to have a better prognosis than those showing rhabdomyosarcomatous elements.
(2) Surgery. Although surgery is the best method of eradicating the tumour when it is localized, many patients will already have metastatic spread by the time the tumour presents clinically. There may well be a place for pre-operative treatment for a few days, followed by careful extensive surgery. There is a limited place for local pulmonary resection in patients with localized metastatic deposits.
(3) Radiotherapy. This may be most usefully employed both before and after operation along with chemotherapy. Irradiation of the lung fields in place of the tumour bed may well be of great benefit to the patient. If given alone, a dosage of up to 3,500-4,000 R. can be given. But in conjunction with actinomycin D, a total of 1,500-3,000 R. should be aimed at. In general, the patient should be giver as high a dosage as can be tolerated, the limits being the age of the child, the size of the field, the area involved, and concomitant chemotherapy. There may well be a place for omitting radiotherapy in the very young child with a completely encapsulated tumour.
(4) Chemotherapy. Actinomycin D has increased the survival rate when added to the other conventional methods of treatment. Dosage has varied from 75 to 120 ,ug./kg. in various centres, and exceptionally to 200 ,ug./kg. Owing to the apparent variable biological activity of the drug, actinomycin D should be given until toxic symptoms appear, particularly depression of the bone-marrow. There is a need for more accurate biological testing of actinomycin D. There is a place for pre-operative treatment with actinomycin D, and a continuous intravenous infusion during operation. Intermittent courses of actinomycin D may well have to be given every 6 weeks at first, and later every 3 months, but so far no limit to the number of post-operative courses has been determined, but they must be continued for at least the first 18 months to 2 years of survival.
When the tumour appears to be resistant to actinomycin D, relief of symptoms and increased survival time can be achieved with vincristine sulphate, in weekly injections of 0 025-0*1 mg./kg., or with cyclophosphamide in doses of 5-10 mg./kg. day for 10 days intravenously, followed orally at about half this dosage. 
